Non-intoxicating
CBD is psychoactive in the pharmacological sense (it is anxiolytic and anticonvulsant), but it is non-intoxicating: it does not produce a “high”.
The record
Evidence & Legal Context
The narrow question is not whether CBD is harmless or a cure-all. It is whether the evidence justifies restricting CBD as a “drug precursor” — and whether that is being decided in the open. The scientific record, international obligations, and court decisions point to the same conclusion: proportionate regulation, not prohibition.
Key facts
An authorised medicine
Purified CBD is an authorised medicine in the EU for certain seizure disorders, assessed by the European Medicines Agency.
Not an internationally controlled drug
The very notice advancing the “precursor” framing records that pure CBD is not controlled under the international drug-control conventions, and that the evidence for its use as a starting material is “limited”.
Real-world evidence
Across Europe, patients — many of them seniors managing chronic conditions — report meaningful benefit. This real-world experience is an essential part of the totality of evidence on safety, tolerability and quality of life, and should not be dismissed because it does not come from randomised trials.
The precursor claim, examined
An evidentially limited hypothesis is not a proven danger.
The restriction proposals rest on the claim that CBD is a “drug precursor”. The document advancing that framing — INCB PP Notice No. 1/2026 — itself records that pure CBD is not controlled under the international drug-control conventions, and that the evidence for its use as a starting material is “limited”. On the science: oral CBD does not meaningfully convert to THC in the human body; the conversion seen in the laboratory requires harsh acidic conditions and is a chemistry-bench artefact, not what happens in patients and not a realistic route to diversion. A restriction would not even address the real problem — the genuinely dangerous synthetic cannabinoids are made from industrial chemicals, not from CBD — so it would leave them untouched while removing the tested, quality-controlled CBD that patients depend on.
Safety, stated honestly
The WHO’s Expert Committee on Drug Dependence found CBD “generally well tolerated, with a good safety profile” (2018). That does not mean CBD is risk-free, and we do not pretend otherwise. Controlled studies have flagged dose-dependent effects on liver enzymes at high therapeutic doses, which is an argument for dosing guidance and labelling. Separately, a chemical-hazard process under EU cosmetics and chemicals law (an ANSES proposal, taken up in an ECHA Risk Assessment Committee opinion in 2026) has proposed classifying CBD as a reproductive-toxicant category 1B. That opinion is hazard-based, contested, and not in force; it belongs to cosmetics and chemical-classification law, not to drug control, and it is precisely the kind of question a transparent, evidence-based assessment should weigh in the open. None of it supports a covert “precursor” restriction. The honest position is pro-regulation: mandatory contaminant testing, accurate labelling, dose guidance and age limits.
The law already constrains this
In Kanavape (Case C-663/18, 19 November 2020) the Court of Justice of the European Union held that CBD is not a narcotic under the 1961 Single Convention, that a member state may not prohibit the marketing of CBD lawfully produced in another member state, and that restrictions on free movement “cannot be based on purely hypothetical considerations”. The CBD in that case was produced in the Czech Republic. National courts have applied the same logic — France’s Conseil d’État struck down a domestic ban on the sale of CBD flower — and the current Czech measure has already drawn EU-law scrutiny through a detailed opinion in the TRIS notification procedure (2025). The legal direction of travel is clear: evidence, not guesswork.
The proportionate model already exists — in Czech law
When the Czech Republic faced a genuinely intoxicating product, it did not reach for prohibition. The Psychomodulatory Substances Act (No. 85/2024) created a regulated category with licensing, an 18+ age limit, and labelling and quality requirements. That is the template for CBD: a transparent, proportionate framework that protects patients and consumers without treating people who rely on lawful CBD as if they were holding a drug precursor. We are asking for the standard the Czech Republic has already written into its own law.
What we do not claim
We do not claim every CBD product is safe — which is why we demand mandatory contaminant testing and accurate labelling. We do not claim CBD treats every condition; the broader clinical evidence is still developing, which is an argument for assessing it transparently. We do not oppose quality standards, age limits, labelling, or enforcement against synthetic cannabinoids. We oppose covert, disproportionate restriction based on evidence the regulator itself calls “limited.”
Downloadable resources
Every source is hosted locally so you can read the primary document yourself.
- Evidence brief — the coalition’s calibrated summary (EN)
- Evidence dossier — full evidence with primary-source citations (EN)
- WHO ECDD Critical Review: Cannabidiol (2018)
- CJEU Judgment, Case C-663/18 “Kanavape” (2020)
- EMA Assessment Report — authorised purified-CBD medicine
- Coalition appeal (evidence & precursor rebuttal, EN)